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Simultaneous Fundoplication and Gastric Stimulation
in a Lung Transplant Recipient With Gastroparesis
and Reflux
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ABSTRACT
Background: Gastroparesis following lung transplanta-
tion can complicate medical management leading to mal-
nutrition, weight loss, and erratic absorption of immuno-
suppressive medications, which are all important factors
in the success of grafts. Gastric electrical stimulation has
been shown to reduce the frequency of nausea and vom-
iting and lead to weight gain in patients with gastroparesis
refractory to standard medical treatment; however, it has
not yet been reported as being used for the treatment of
gastroparesis in lung transplant recipients.
Methods: We report the case of a female bilateral lung
transplant recipient suffering from severe gastric reflux
and severe gastroparesis, who was successfully treated
with simultaneous creation of a laparoscopic Nissen fun-
doplication and placement of a gastric stimulator.
Results: The patient noted an immediate and sustained
decrease in her symptoms of nausea and vomiting, and an
increased appetite, and less variability in the serum levels
of her immunosuppressive medication.
Conclusion: Lung transplant recipients with severe gas-
troparesis and reflux may benefit from Nissen fundoplica-
tion and gastric electrical stimulation.
Key Words: Gastroparesis, Lung transplant, Reflux, Gas-
tric stimulation.
INTRODUCTION
Gastroparesis, or delayed gastric emptying, is a recog-
nized complication following lung transplantation, with
incidences reported between 24% and 83%.1 Gastropare-
sis can complicate medical management in these patients,
leading to complications like malnutrition, weight loss,
electrolyte disturbances, aspiration pneumonia, and vari-
able absorption of their immunosuppressive medications,
which may place them at increased risk of rejection. Fre-
quent nausea, vomiting, and gastroesophageal reflux can
also lead to aspiration pneumonitis. Following lung trans-
plant, this condition may predispose the patient to oblit-
erative bronchiolitis, a form of chronic lung transplant
rejection.2 The inability to take scheduled medicationsand
the variability in absorption of these medications can also
be challenging in these sensitive patients, and can
threaten the well being of the allograft. Gastroparesis
following organ transplantation, specifically lung and
combined heart-lung transplantation is a well-recognized
phenomenon. The pathogenesis of gastroparesis in this
group of patients is unknown; however, it is thought to be
multifactorial and may involve vagal nerve injury or dys-
function or viral illness secondary to immune suppression,
which can cause damage to the myenteric nervous sys-
tem.3 The question of whether the cause is related to the
toxic effects of immunosuppressive medications, specifi-
cally cyclosporine, has also been raised but is unlikely
considering gastroparesis is uncommon following both
renal and liver transplantation.2
Gastric electrical stimulation (GES) has been shown in
both controlled and uncontrolled studies4 to reduce the
frequency of nausea and vomiting and lead to weight gain
in patients with gastroparesis refractory to standard med-
ical treatment; however, little evidence supports the use of
gastric stimulation in lung transplant recipients. Accord-
ingly, patients following lung transplantation can also
experience significant gastric reflux, which can pose the
same risks of aspiration pneumonia and threaten the
graft.2 This patient was experiencing severe symptoms of
both gastric reflux and gastroparesis, and this combination
of simultaneous treatment with a Nissen fundoplication
and implantation of a gastric stimulator has not been
reported in the medical literature.
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CASE REPORTCASE REPORT
A 55-year-old female was referred to the GI surgery clinic
by her pulmonologist in February 2007, five months after
a successful bilateral lung transplant for end-stage pulmo-
nary fibrosis. Her maintenance immunosuppressive regi-
men consisted of Prednisone 10 mg PO BID, mycophe-
nolate mofetil 250 mg PO TID, and tacrolimus 1mg PO
BID. The patient complained of severe heartburn with
regurgitation and symptoms of intractable nausea and
vomiting, early satiety, and loss of appetite, which began
shortly after her lung transplantation and had been pro-
gressively worsening. The patient’s weight had dropped
to 89 lb (BMI13.5) despite oral nutritional supplements.
Preoperative evaluation consisted of an upper gastrointes-
tinal series that revealed extensive episodes of reflux to
the level of the clavicles. An intraesophageal pH monitor-
ing study confirmed acid (pH4) reflux with 444 episodes
recorded in 12 hours (normal 50). Esophageal manom-
etry showed low-normal LES pressure of 14 mm Hg (10 to
40 mm Hg normal) and no evidence of achalasia. Her
gastric emptying study revealed delayed gastric emptying
with a half-time of greater than 5 hours, which is greater
than 333% of normal. The patient had failed medical
therapy, as her symptoms continued to worsen despite
being on omeprazole 20 mg PO daily, lansoprazole 30 mg
PO BID, promethazine 12.5 mg q 4 hours, and metoclo-
pramide 10 mg PO daily for greater than 4 months.
After multiple discussions with the pulmonologist, anes-
thesia team, and the patient, it was determined that simul-
taneous operations consisting of laparoscopic implanta-
tion of the Enterra gastric pacemaker and laparoscopic
Nissen fundoplication would be performed as therapy for
this patient’s gastroparesis and acid reflux. Although the
patient’s LES was in the normal range, she was experienc-
ing significant reflux and had failed maximum medical
therapy with the medications listed above and had already
experienced one episode of lung rejection complicated by
aspiration. The possibility that all symptoms were related
to the gastroparesis alone was discussed; however, gastric
emptying does not improve following GES and, given
such frequent and large-volume reflux, the team decided
that GES without antireflux protection would be insuffi-
cient as a solitary therapy in this individual.
The patient underwent treatment with a laparoscopic Nis-
sen fundoplication and simultaneous placement of an
Enterra (Model 3116 neurostimulator, Model 4351 leads,
Medtronic, MN) gastric stimulator. Prior to initiating the
abdominal component of the surgery, endoscopy was
performed which showed posterior erosion of the lower
to middle one third of the esophagus, and a moderate-
sized bezoar was seen in her stomach. The Nissen fundo-
plication was performed first, followed by implantation of
the Enterra gastric pacemaker using the standard tech-
nique.5 The patient’s hiatus was without herniation, and a
single stitch closed the hiatus posteriorly. The fundoplica-
tion was done over a 50 french bougie with three 0 silk
interrupted sutures spanning 2 cm top-to-bottom. The 2
highest short gastric vessels were transected, and the sur-
faces of the fundoplication were without tension. For the
gastric pacemaker portion of the procedure, the 2 elec-
trodes were placed 1cm apart, 9cm to 10cm proximal to
the pylorus along the greater curvature of the stomach’s
inferior surface. Simultaneous EGD was performed to ex-
clude perforation.
The patient’s perioperative course was uncomplicated.
The generator was programmed with the common initial
settings of 3 Volts, with a 12 Hz cycle (5 seconds off and
0.1 seconds on). Initial follow-up at 3 weeks to 4 weeks
revealed early improvements in symptoms. Postoperative
studies with GES have shown unpredictable improve-
ments in gastric emptying; therefore, postoperative gastric
emptying studies are not routinely performed in these
patients and was not performed in this patient. This pa-
tient had no postoperative complications. She was then
contacted by telephone for follow-up 5 months later, and
a survey assessing the severity of her symptoms both prior
to and after the surgery was administered. The patient
reported that she first noticed improvements in her symp-
toms 3 weeks to 4 weeks after the surgery was performed.
She had marked improvements in her symptoms of nau-
sea, vomiting, and retching, and reported a significant
improvement in her appetite. She denied any symptoms
of heartburn and no longer required the use of lansopra-
zole or omeprazole. The only antiemetic she continued to
take was metoclopramide 12.5 mg one time per day,
which was a significant reduction from her 6 times per day
preoperatively. She has had continued weight gain since
her surgery up to 142 lb, BMI21.6. She also reported that
her quality of life went froma0t oa4o na0 -t o5-point
severity scale. She is now tolerating her oral medications
well, which has resulted in less variation in her serum
Tacrolimus levels.
DISCUSSION
The exact cause of gastroparesis following lung transplant
is unknown and is thought to be multifactorial with the
likely mechanism being injury to the vagus nerve during
the surgery, either from direct mechanical injury or ther-
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whether the cause is related to the toxic effects of immu-
nosuppressive medications, specifically cyclosporine, has
also been raised but is unlikely considering that gastropa-
resis is uncommon following both renal and liver trans-
plantation.2 In either case, gastroparesis following lung
transplantation can be the cause of numerous complica-
tions, most importantly, aspiration pneumonia leading to
obliterative bronchiolitis, a form of chronic rejection.
Compromised oral intake may lead to the inability to take
scheduled medications as well as poor medication ab-
sorption, which could endanger graft function in these
immune suppressed patients. As a result of these chronic
symptoms, patients have difficulty meeting nutritional and
caloric needs. They may eventually require supplemental
feeding via tube feeding. Current medical treatments in-
clude administration of prokinetic and antiemetic drugs to
control symptoms. Patients who do not respond to these
drugs can only be managed by enteral or TPN support.
In past reports,2 severe gastroparesis in either lung or
combined heart-lung transplants has generally been man-
aged medically with prokinetic or antiemetic pharmaco-
logic therapy, with variable results. The only reports of
surgical management include the successful use of gastric
bypass surgery in 2 lung transplant recipients,6 and the
successful use of TENS therapy in 2 lung transplant pa-
tients.7 The only published report of the use of gastric
pacing in this population has been one report of the
successful use of a gastric pacemaker in a single patient
with a combined heart-lung transplant.1 Other procedures
were considered along with the risks and benefits of
performing various procedures in this high-risk patient on
immunosuppressive therapy; a pyloroplasty or gastrojeju-
nostomy was not done to avoid possible luminal injury or
leakage in this high-risk patient. Because the patient had
no evidence of a pyloric scar on preoperative imaging or
EGD, endoscopic dilation was not deemed the best mode
of treatment.
CONCLUSION
To our knowledge, this is the first report of using gastric
pacemaker therapy for the successful treatment of severe
gastroparesis in a lung transplant recipient. This case is
unique in that it involved the simultaneous performance
of a Nissen fundoplication to relieve the symptoms of
posttransplant gastric reflux as well. Since the surgery, the
patient has had a marked increase in weight, a significant
reduction to resolution of her gastroparesis-related symp-
toms, and is able to tolerate her oral immunosuppressive
medications. Because of the combining of the 2 opera-
tions, the patient has been able to improve her weight,
reduce her symptoms, and improve her quality of life;
perhaps as important, she has reduced her risk for aspi-
ration of stomach contents, which greatly threatened the
viability and longevity of her graft. We recognize that
there are limitations to analyzing and scoring patient’s
symptoms both pre- and posttherapy retrospectively, and
definitive prospective evaluation should follow this initial
report.
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